1. Home
  2. BHC vs MESO Comparison

BHC vs MESO Comparison

Compare BHC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bausch Health Companies Inc.

BHC

Bausch Health Companies Inc.

HOLD

Current Price

$4.78

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$15.45

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BHC
MESO
Founded
N/A
2004
Country
Canada
Australia
Employees
N/A
81
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
BHC
MESO
Price
$4.78
$15.45
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$8.00
N/A
AVG Volume (30 Days)
2.1M
137.6K
Earning Date
04-29-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
423.08
N/A
EPS
N/A
N/A
Revenue
$8,724,000,000.00
N/A
Revenue This Year
$4.61
$629.74
Revenue Next Year
N/A
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.57
$10.32
52 Week High
$8.69
$21.50

Technical Indicators

Market Signals
Indicator
BHC
MESO
Relative Strength Index (RSI) 36.06 59.54
Support Level N/A $13.71
Resistance Level $6.31 $16.11
Average True Range (ATR) 0.19 0.49
MACD -0.04 0.16
Stochastic Oscillator 26.06 88.92

Price Performance

Historical Comparison
BHC
MESO

About BHC Bausch Health Companies Inc.

Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: